Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
seekingalpha.comNurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansionsseekingalpha.comJun 9
reuters.comRoche sticks to German investment after Eli Lilly cutsreuters.comJun 9
seekingalpha.comRoche Holding AG (RHHBY) Shareholder/Analyst Call Transcriptseekingalpha.comJun 8
gurufocus.comRoche's $2.3 Billion Nurix Deal Sends Shares Movinggurufocus.comJun 8
zacks.comRoche, Nurix Team Up to Advance BTK Degrader Bexobrutidegzacks.comJun 8